Literature DB >> 16886000

Coxsackie adenovirus receptor and alpha nu beta3/alpha nu beta5 integrins in adenovirus gene transfer of rat cochlea.

F Venail1, J Wang, J Ruel, E Ballana, G Rebillard, M Eybalin, M Arbones, A Bosch, J-L Puel.   

Abstract

This study was designed to determine whether Coxsackie adenovirus receptor (CAR) and alpha nu beta3/alpha nu beta5 integrin co-receptors are involved in adenovirus gene transfer in the rat cochlea. We find that CAR and integrin co-receptors are expressed in every cell subtype transduced by the adenoviral vector Ad5 DeltaE1-E3/cytomegalovirus/green fluorescent protein (GFP) on cochlear slices in vitro. The spiral ganglion neurons, which do not express CAR, were not transduced by the virus. Blocking these receptors by monoclonal antibodies decreased transgene expression, whereas disrupting tight junctions with ethylenediaminetetraacetic acid led to an increased transgene expression. However, sensory hair cells and strial cells also expressing CAR and alpha nu integrins were not transduced by the vector. GFP expression was also studied in vivo. Perilymphatic perfusion of adenovirus in vivo did not affect hearing and only cells lining the perilymphatic spaces were transduced. Endolymphatic perfusion resulted in low-frequency hearing loss and although some cells of the organ of Corti were efficiently transduced, the sensory and the strial cells were not. Transduced sensory and strial cells were occasionally observed in cochleas after single shot of adenovirus. Pretreatment with anti-CAR and anti-alpha nu antibodies decreases GFP expression in vivo, suggesting that the CAR/alpha nu integrin pathway is involved in adenovirus transduction in the cochlea.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886000     DOI: 10.1038/sj.gt.3302826

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  18 in total

1.  Hyaluronic acid enhances gene delivery into the cochlea.

Authors:  Seiji B Shibata; Sarah R Cortez; James A Wiler; Donald L Swiderski; Yehoash Raphael
Journal:  Hum Gene Ther       Date:  2012-02-08       Impact factor: 5.695

Review 2.  Inner ear manifestations in CHARGE: Abnormalities, treatments, animal models, and progress toward treatments in auditory and vestibular structures.

Authors:  Daniel I Choo; Kareem O Tawfik; Donna M Martin; Yehoash Raphael
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-10-30       Impact factor: 3.908

Review 3.  Outlook and future of inner ear therapy.

Authors:  Jenna Devare; Samuel Gubbels; Yehoash Raphael
Journal:  Hear Res       Date:  2018-05-17       Impact factor: 3.208

Review 4.  Emerging Gene Therapies for Genetic Hearing Loss.

Authors:  Hena Ahmed; Olga Shubina-Oleinik; Jeffrey R Holt
Journal:  J Assoc Res Otolaryngol       Date:  2017-08-16

5.  Optimizing atoh1-induced vestibular hair cell regeneration.

Authors:  Hinrich Staecker; Christina Schlecker; Shannon Kraft; Mark Praetorius; Chi Hsu; Douglas E Brough
Journal:  Laryngoscope       Date:  2014-06-17       Impact factor: 3.325

Review 6.  Gene therapy in the inner ear using adenovirus vectors.

Authors:  Jacob Husseman; Yehoash Raphael
Journal:  Adv Otorhinolaryngol       Date:  2009-06-02

7.  Adenoviral vectors for improved gene delivery to the inner ear.

Authors:  Mark Praetorius; Douglas E Brough; Chi Hsu; Peter K Plinkert; Susanna C Pfannenstiel; Hinrich Staecker
Journal:  Hear Res       Date:  2008-12-07       Impact factor: 3.208

8.  An in vitro model system to study gene therapy in the human inner ear.

Authors:  B W Kesser; G T Hashisaki; K Fletcher; H Eppard; J R Holt
Journal:  Gene Ther       Date:  2007-06-14       Impact factor: 5.250

Review 9.  Gene therapy for the inner ear.

Authors:  Hideto Fukui; Yehoash Raphael
Journal:  Hear Res       Date:  2012-12-21       Impact factor: 3.208

10.  Gene transfer using bovine adeno-associated virus in the guinea pig cochlea.

Authors:  S B Shibata; G Di Pasquale; S R Cortez; J A Chiorini; Y Raphael
Journal:  Gene Ther       Date:  2009-05-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.